Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pharnext S.C.A.
With
Ascopharm Groupe Novasco
Patients having completed the previous 12-week PLEODIAL-I study were eligible to receive PXT00864 in this 24-week open-label extension PLEODIAL-II study in order to collect some additional long-term data regarding the safety and the potential effect of PXT00864 on cognitive and behavioural impairments.
Age
60–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Mild Alzheimer's Disease patient who was included in PLEODIAL-I study
Mini Mental State Examination (MMSE) score greater or equal to 20
You may not be if
Patient who was not compliant with the previous PLEODIAL-I study protocol
Patient who experienced significant adverse events which necessitated treatment discontinuation during the PLEODIAL-I study
